Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of NBI-921352 as adjunctive therapy in focal onset seizures
2021-004265-12Phase 2Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zandatrigine in Focal onset seizure, sponsored by Neurocrine Biosciences. Primary endpoint: Serious treatment-emergent adverse events and discontinuations. Started Nov 2021; status: completed.
02
Drugs
zandatrigine
03
Conditions
Focal onset seizure
Beyond the preview
Go deeper on 2021-004265-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004265-12.